<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8588">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00823199</url>
  </required_header>
  <id_info>
    <org_study_id>ICFV12/02</org_study_id>
    <nct_id>NCT00823199</nct_id>
  </id_info>
  <brief_title>An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia</brief_title>
  <official_title>An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bronx Psychiatric Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bronx Psychiatric Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a four week open label trial of ALLOPURINOL to the treatment regime of ten (10)
      poorly responsive patients with schizophrenia, monitoring their response and side-effects.
      No change in medication is required.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Positive and Negative Syndrome Scale (PANSS) Measures Symptoms of Schizophrenia</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Symptom scale Score 30 (best, no symptoms of schizophrenia) to 210 (worst)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Simpson Angus Scale for Parkinsonism</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Measures drug induced parkinsonism, score 0 (best, no Parkinsonism) to 36 (worst)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Allopurinal treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allopurinal 300mg once daily by mouth for four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinal</intervention_name>
    <description>300mg once daily by mouth for four weeks</description>
    <arm_group_label>Allopurinal treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with schizophrenia and poor response (no prospect of discharge because of
             symptoms)

        Exclusion Criteria:

          -  Over 65

          -  Renal or liver disease

          -  Diabetes

          -  Hypertension

          -  Taking thiazides or ACE inhibitors
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nigel Bark, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bronx Psychiatric Center</affiliation>
  </overall_official>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 20, 2015</lastchanged_date>
  <firstreceived_date>January 14, 2009</firstreceived_date>
  <firstreceived_results_date>April 25, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bronx Psychiatric Center</investigator_affiliation>
    <investigator_full_name>Nigel Bark MD</investigator_full_name>
    <investigator_title>Director Schizophrenia Research</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Ten subjects were recruited, in-patients in a State Hospital, between 2005 and 2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Allopurinal Treatment</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="38" spread="9.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Positive and Negative Syndrome Scale (PANSS) Measures Symptoms of Schizophrenia</title>
        <description>Symptom scale Score 30 (best, no symptoms of schizophrenia) to 210 (worst)</description>
        <time_frame>baseline and 4 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Two subjects withdrew before the first week's evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>Allopurinal Treatment</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Positive and Negative Syndrome Scale (PANSS) Measures Symptoms of Schizophrenia</title>
            <description>Symptom scale Score 30 (best, no symptoms of schizophrenia) to 210 (worst)</description>
            <units>scores on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="95" spread="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>End</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="75" spread="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Simpson Angus Scale for Parkinsonism</title>
        <description>Measures drug induced parkinsonism, score 0 (best, no Parkinsonism) to 36 (worst)</description>
        <time_frame>baseline and 4 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Allopurinal Treatment</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Simpson Angus Scale for Parkinsonism</title>
            <description>Measures drug induced parkinsonism, score 0 (best, no Parkinsonism) to 36 (worst)</description>
            <units>score on scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.37" spread="0.74"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>End</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.75" spread="3.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Uric Acid Level</title>
        <time_frame>Baseline to 4 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>2 subjects had missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Allopurinal Treatment</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Uric Acid Level</title>
            <units>mg/dL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.9" spread="1.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>End</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.8" spread="0.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the 4 week study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nigel Bark MD</name_or_title>
      <organization>Bronx Psychiatric Center</organization>
      <phone>7188625429</phone>
      <email>Nigel.Bark@omh.ny.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
